张文宏团队公布广谱抗猴痘药物研发进展，将进入临床审批阶段

Core Insights - The Shanghai Infectious Disease and Immunology Technology Innovation Center has made significant progress in developing a new antiviral drug for monkeypox, which is set to enter clinical approval soon [1] Group 1: Research and Development - The research team led by Zhang Wenhong has developed a novel antiviral drug, ODE-(S)-HPMPA formate, which has shown stronger and broader efficacy compared to the antiviral drug used in clinical studies by the U.S. National Institutes of Health [1]